Advertisement
Advertisement
May 28, 2014
Japanese Postmarket Surveillance Data for Zilver PTX Presented at EuroPCR 2014
May 29, 2014—At last week’s EuroPCR 2014 meeting, Hiroyoshi Yokoi, MD, of Fukuoka Sanno Hospital presented 1-year data from from a postmarket surveillance study of 907 Japanese patients who were treated using the Zilver PTX peripheral drug-eluting stent (Cook Medical) in the superficial femoral artery. This study is intended to evaluate real-world use of the Zilver PTX device, which was approved in Japan and the United States in 2012, and in Europe in 2009.
Of the patients enrolled, 838 were eligible for 1-year follow-up. The mean lesion length in this group was 14.7 cm. Key among the data presented by Dr. Yokoi were a 91.4% rate of freedom from target lesion revascularization at 1 year, with 84.8% primary patency, a figure similar to those shown in previous Zilver PTX studies.
“We’re very pleased with the data from the Japan PMS study because the study included a broad range of lesion types and lengths similar to what doctors treat on a daily basis. Like our other studies, this evaluation shows that for most patients there is an enduring drug effect from Zilver PTX a year after implantation,” commented Mark Breedlove, global leader for Cook Medical’s Peripheral Interventional (PI) division, in the company's press release.
Advertisement
Advertisement
